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1. Introduction
Eosinophilic gastrointestinal diseases (EGIDS) are immune mediated diseases with varying
clinical presentations but are characterized pathologically by eosinophilic infiltrate of the
epithelium of the gastrointestinal tract. Eosinophilic esophagitis has become the most recog‐
nized entity over the last twenty years and great strides have been made to understand it. In
the 1970s and 1980s, case reports of patients with esophageal eosinophilia were reported but
the significance of these findings was not known or were attributed to GERD. In the 1990s the
field of Pediatric Gastroenterology was emerging and endoscopy of children became more
common. In addition, pediatric gastroenterologists knew that inflammation could occur
despite macroscopically “normal” appearing tissue and therefore routine biopsies during
endoscopy have been standard of care. This led to wider understanding of the clinical
presentation and outcomes of children with prominent eosinophilia of the esophagus. These
children did not respond to the typical antacid regimen. They had a wide range of clinical
symptoms including vomiting, regurgitation, and abdominal pain and feeding refusal. It was
also noted that many had concurrent atopic diseases including food allergies, eczema and
asthma.[1-4] The fields of allergy and gastroenterology were beginning to converge on a
disease process that would prove more complex to manage than many other food allergies.
Today gastroenterologists and allergists have come to depend on one other in the management
of these patients.
Eosinophilic esophagitis is becoming a recognized common cause of esophagitis in children
and adults. The most current definition comes from the consensus statement published in 2011
in The Journal of Allergy and Clinical Immunology. The new criteria is less restrictive then
definitions put forth in the past. In addition, the authors changed the abbreviation from EE to
EoE because across disciplines EE can have different meanings (e.g. erosive esophagitis). This
expert panel wanted to conceptualize the definition so that it could represent the wide range
of patients and clinical scenarios. The expert panel agreed upon the definition that “eosino‐
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philic esophagitis represents a chronic, immune/antigen-mediated esophageal disease
characterized clinically by symptoms related to esophageal dysfunction and histologically by
eosinophil-predominant inflammation”.[5]
Histologic criteria include the presence of ≥15 eosinophils per high power field on esophageal
biopsy. This requirement should make diagnosis more standardized; however, the definition
of “high power” field can vary and therefore change the number of eosinophils reported. They
did allow for exceptions to the 15 per high power field in the case of other histologic features
including microabscess, superficial layering or extracellular eosinophilic granules. [5]
2. Epidemiology
The epidemiology of eosinophilic esophagitis is becoming better understood. From multiple
studies it has become apparent that EoE effects males at least 3 times more frequently than
females.[6-11] EoE patients are more likely to have atopic disease than the general population.
[12-17] Whites appear to have a higher incidence than other races. All age groups are effected
including infants and there is a report of a 98 year old with EoE.[11] However, most patients
are children, adolescents and adults younger than 50 years old. In a large epidemiological
study the prevalence was highest in men age 35-39 years old.[18]
The prevalence and incidence has been hard to determine. Data suggests that the incidence
and prevalence is increasing. While it could be hypothesized that this was due to increased
awareness, retrospective studies of esophageal biopsy specimens have indicated that the
incidence and prevalence are truly increasing. This increase in incidence and prevalence
remains when adjusted for the increased use of endoscopy.[19, 20] The incidence has been
reported to be 6 to 13 cases per 100,000 in studies from the United States, Canada, and
Switzerland.[13, 21-23] Denmark and Netherlands report lower incidence at less than 2 cases
per 100,000.[24] The prevalence has been estimated anywhere between 10-80 cases per 100,000,
depending on the population being studied.[18] A recent study using a large US database of
health insurance claims of over 35 million patients showed a period prevalence of 56.7 per
100,000 through the years 2009-2011.[18]
3. Differential diagnosis
The differential diagnosis for esophageal eosinophilia includes celiac disease, Crohn’s disease,
esophageal achalasia, connective tissue disorders, drug reactions, hypereosinophilic syn‐
dromes and graft versus host disease and these disorders need to be ruled out prior to making
the diagnosis of EoE. The most problematic differential diagnosis is gastroesophageal reflux
(GERD). In the past, eosinophilia was attributed to GERD. During the treatment of patients
with prominent eosinophilic infiltrate it was noted that they were less responsive to antacids,
both clinically and histologically. Trying to understand the relationship between GERD,
eosinophilia of the esophagus and EoE is one of the most important and difficult tasks facing
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clinicians who diagnose and treat EoE. Food allergy is also a major component of EoE and
dietary therapy can be first line therapy in many cases. The relationship between food allergy
and EoE is also only partially realized.
4. Eosinophils
An understanding of EoE requires a review of the primary effector cell in the pathology, the
eosinophil. New developments in our understanding of eosinophil responses reveal that their
role in immunology goes beyond attacking helminthes. Eosinophils are highly complex
hematopoietic cells which participate actively in the immune response. First, eosinophil
released granule products such as eosinophil cationic protein (ECP) are capable of chemoat‐
tracting antigen presenting cells such as macrophages.[25] This granule is believed to have
direct antimicrobial action as well as directing macrophage recruitment to the site of ECP
release. Recruitment of myeloid dendritic cells to draining lymph nodes, a critical step to
specific immune responses, is influenced by eosinophils.[26] Further downstream, in the
immunologic response, eosinophils are capable of regulating B cell numbers via influencing
B cell proliferation.[27]Further evidence that eosinophils can participate in the immune
response to pathogens is the presence of pattern recognition receptors on the eosinophil
receptor. These toll-like receptors, NOD, dectin-1 and RAGE receptors are innate, non-specific
responses to various elements of the microbial cell wall which result in initiating and ampli‐
fying the host immune response.[28] Studies have demonstrated toll-like receptor expression
on eosinophils occurs in EoE.[29] The immunobiology of the eosinophil is intimately related
to the allergic response. The understanding that eosinophils and allergies are related in the
experimental research in EoE is new. Due to the recent gains in the knowledge of the patho‐
physiology of EoE there are gaps in the clinical applications. Therefore other atopic diseases,
such as asthma, will be utilized as a model to demonstrate the eosinophil’s complex capabili‐
ties. Particular emphasis will be placed on those components of the allergic response which
likely contribute to EoE.
Eosinophils are hematopoietic cells, derived from the bone marrow. Normal hematopoiesis
involves tight control on eosinophil differentiation from a common progenitor cell. New data
suggests that eosinophils and basophils share a common lineage with the erythrocytes and
megakaryocytes.[30] However, commitment from the common progenitor cell into an
eosinophil progenitor (CD 34+IL5R+) requires the presence of IL-5 predominately, but GM-
CSF and IL-3 also affect eosinophilopoiesis.[31] Sources of IL-5 in the bone marrow include
the bone marrow stromal cell, hematopoietic cells, T lymphocytes and bone marrow endothe‐
lial cells.[32] Data suggests that a newly discovered hematopoietic cell ILC2, an innate
lymphoid cell present locally in peripheral tissues, may be capable of controlling eosinophi‐
lopoiesis. [33] These ILC2 cells produce profound amounts of IL-5 which is released into the
systemic circulation directing the bone marrow to increase eosinophil production. IL-5’s role
in EoE is under investigation, as it has been found in the blood vessels of esophageal biopsies
of pediatric EoE patients.[34]
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Increases of eosinophil progenitor cells and mature eosinophils in the bone marrow are
described in both human and murine studies of allergen sensitization and occurs independent
of T lymphocytes or specific IgE activation of the bone marrow.[35-37] This model of acceler‐
ated response of eosinophilopoiesis is linked to an acute response to allergens in multiple
strains of mice. However, the eosinophilic potential to have ongoing bone marrow eosinophilia
linked to chronic disease and fibrosis development in the asthmatic airway may not be a
universal response in the disease and may require a specific genetic background. [38] This may
have implications for disease severity in both asthma and EoE in determining which individ‐
uals have disease progression due to eosinophil influenced severe fibrosis.
Eosinophil progenitor cells may be able to finish differentiation to mature eosinophils locally
in the effected peripheral tissue, like the esophagus, stomach and intestines. Eosinophil
progenitors are released into the peripheral blood stream in asthmatic individuals and are
attracted to peripheral tissues that are involved in the asthmatic response.[39] Interestingly,
topical glucocorticoid therapy in asthma decreases eosinophil progenitors circulating in the
peripheral blood. [37] In addition, interfering with chemotactic signaling of eosinophil
progenitors early in the asthmatic response to allergen challenge to the lung decreases lung
eosinophil progenitor and mature eosinophil numbers.[39] This demonstrates that control of
eosinophilopoiesis may be an important component to controlling eosinophil derived diseases.
Investigations into the potential for eosinophilic mucosa to support eosinophilopoiesis could
provide a key understanding of the pathophysiology of EoE.
Progenitor cells are attracted to peripheral tissue and so are mature eosinophils. The primary
chemokines responsible for recruiting mature eosinophils to their targets are IL-5, eotaxin,
MCP and RANTES.[40] These cytokines are produced by inflammatory cells present in the
tissue during allergic responses. Other cytokines released by tissue cells in the allergic response
such as IL-4 and IL-13 may play an indirect role in eosinophil trafficking role by increasing
eotaxin expression. Epithelial cell production of IL-5, IL-13 and eotaxin has been found in
biopsies obtained from pediatric EoE patient.[34, 41] and are decreased with glucocorticoid
therapy in EoE. Blockade of these chemotactic signals results in reduction of the eosinophilic
response peripherally.
Once recruited to peripheral tissues, eosinophils are activated by multiple extracellular
proteins and cytokines. Eosinophils have integrins on their surface that interact with the
extracellular matrix. This interaction can increase survival of eosinophils and also increase
recruitment of more eosinophils through several pathways. For instance, platelet-activating
factor primes eosinophil adherence to tissue through both beta-1 and beta-2 integrins.[40]
Periostin, an extracellular matrix protein, is a strong chemotactic agent.[42] Periostin produc‐
tion has been shown to be inducible by transforming growth factor-beta and IL-13 after allergen
exposure in a corresponding murine model of EoE.[43] Periostin exists in both the human lung
and esophagus. Levels of periostin have been found to be higher in EoE patients than controls.
Increased accumulation of eosinophils was correlated to increased levels of periostin in these
studies.[44] Therefore it may be that periostin recruits and retains eosinophils at the peripheral
tissue in eosinophilic disease. Fibronectin is another extracellular matrix protein that binds
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with Beta-1 integrin (VL-4) on the surface of eosinophils. This interaction has shown to enhance
eosinophil survival.[45]
Therapeutic approaches that target the adhesion and interactions of eosinophils with tissue
and plasma elements will be difficult due to multiple interactions and pathways involved
once eosinophils are activated. Highly activated integrin molecules on eosinophils are asso‐
ciated with survival independent of exogenous IL-5 signaling.[42, 46] Eosinophils activated
by endothelial fibronectin will also autologously produce survival factors including IL-5,
IL-3 and GM-CSF.[47] Dexamethasone reduces the endothelial production of these survival
factors.[48] However, this autologous production of survival factors from adherent stimulat‐
ed eosinophils will make development of a novel single agent anti-cytokine therapy to treat
EoE more difficult. The capability of the eosinophil to survive without exogenous IL-5 will
also limit the use of anti-IL-5 therapies as sole pharmacotherapy in the armentarium of EoE
treatment.
Negative regulators of chemotaxis and survival of eosinophils include, IL-12 which reduces
platelet activating effects on eosinophils and reduces eotaxin dependent tissue migration.
[49] Activation of the Siglec-F receptor on eosinophils induces eosinophil apoptosis.  IL-5
and GM-CSF failed to rescue eosinophils from this fate, suggesting that this may be one
viable way to eliminate eosinophils once they have migrated to peripheral tissues.[50] A
proof of concept study has been performed in a murine model of allergic EoE in which
Siglec-F activation resulted in decreased eosinophil numbers in the esophagus.[51] Other
inhibitory mechanisms which the immune system uses, such as FOXP3, CD25+and TH17
may play a role in this process.[52] While TGF-beta has been linked to fibrotic activity it
also has an apoptotic effect on eosinophils as a negative feedback regulatory mechanism.
[50-52]  The only currently used therapeutic  agent which prevents eosinophil  priming in
eosinophilia  is  glucocorticoids.[53]  Glucocorticoid  effect  is  thought  to  be  from  altering
eosinophil and other immune mediated cell cytokine production. Glucocorticoids also bias
hematopoiesis towards neutrophil production.
5. IgE mediated allergic mechanisms
Allergy is the immune pathway mediated by IgE binding to allergen and subsequently
activating mast cell release of prototypic cytokines. These preformed mediators include
histamine, tryptase, IL-5, cysteinyl leukotrienes amongst other cytokines. This is known as the
immediate phase reaction. It is responsible for the wheal and flare during functional skin prick
testing to allergens, and immediate airway contraction in asthma. These agents also cause
vomiting, diarrhea, and abdominal cramping after an IgE mediated food allergy. Release of
these agents subsequently causes an inflammatory recruitment of eosinophils and lympho‐
cytes, known as the late phase reaction.
Some EoE patients appear to have this basic immediate phase response. IL-5 and IL-13 correlate
with eotxin-3 and eosinophil levels.[44] In addition some EoE patients have both eosinophils
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and mast cells in esophageal biopsies.[54] In fact, the presence of IgE bearing intraepithelial
mast cells in EoE patients distinguished allergic EoE patients from non-allergic EoE patients.
[17] Mastocytosis and degranulated mast cells have been found in the biopsies of EoE patient.
[55] In asthma, contact of eosinophils with mast cells was the most potent driver of eosinophil
survival.[56] The presence of IL-13 in EoE would also increase IL-4 and IL-13 and cause B cell
isotype switching to IgE production.
In addition, TH2 cell production of cytokines such as IL-4, 5, 13 is a hallmark feature of
allergy. The importance of IL-13 in immediate phase reactions is demonstrated by inhibi‐
tion of IL-13 by an anti-IL-13 Fab fragment resulting in decreased eosinophilia, inflamma‐
tory  infiltrate  and  airway  hyper-reactivity  in  a  murine  model  of  asthma.[57]  Anti-IL5
therapy is being investigated in eosinophilic diseases such as asthma and Churg Strauss
disease. Anti-IL4 therapeutic targets are being investigated in atopic dermatitis. These Th2
driven processes are also amplified by innate lymphoid cells (ILC2) at the mucosal surface.
[58]  These  cytokines  along  with  TGF-beta  encourages  eosinophil  induced  fibrosis  and
motility disorders in EoE patients.[43]
Some allergens will also actively participate in the subsequent immediate phase reactions.
Allergens which are proteases (insect derived or fungal) have been found to deceitfully act in
an innate fashion with initial exposure. These allergic proteases activate IL-25, IL-33 and TSLP
mucosal production resulting in ILC2 activation in the lung tissue.[59] In this study ILC2
expressed IL-5 and ILl-13. Eosinophil recruitment has been identified in the lung with fungal
chitinase exposure.[60] Interestingly a murine model of EoE induced by cockroach and dust
mite has been described.[61] This model was characterized by esophageal eosinophilia,
mastocytosis, increased IgE, IL-5 and eotaxin after cockroach and dust mite exposure but not
cat or dog exposure. Protease inhibition in a murine asthma model with cockroach extract
reduced eosinophil counts in BALF.[62]
6. GERD and eosinophils
In 1982 Winter, et al. described esophageal eosinophils in series of pediatric patients and
concluded that increased eosinophils was a marker for more severe GERD.[63] Four theories
have been proposed for the association between esophageal eosinophilia and GERD. First, EoE
and GERD can both be present but they are unrelated. The 2011 consensus statement has
chosen not to exclude the diagnosis of EoE even in the setting of abnormal pH probe. This
recognizes the hypothesis that GERD and EoE can coexist. The basis of this hypothesis from
an epidemiologic view, is that approximately 20% of adults have GERD so a certain percentage
of adult EoE patients will also have GERD. [64, 65] In addition, pathologic GERD is rare in
children with EoE.[66] This latter claim could be disputed since pH monitoring is not always
done in children and there are no standardized norms. However, other research has found
higher incidences of GERD among adult patients with EoE.[67, 68]
Another proposed mechanism is that GERD causes esophageal eosinophilia but it is not
eosinophilic esophagitis. The criteria for the number of esophageal eosinophils to be greater
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than 20 was suggested after it was noted that patients with more than 15 eos/hpf were less
likely to respond to anti-reflux medication.[69, 70] In lab models it has been shown that acid
stimulates the release of many substances that could potentially attract and activate eosino‐
phils. These substances include platelet activating factor, interleukin-8, eotaxin-1, eotaxin-2,
exotoxin-3, macrophage inflammatory protein and RANTES (regulated upon activation of
normal T cell expressed and secreted).[71-76] These factors have also been isolated from biopsy
specimens from patients with GERD.[76] However, it is still not known if the eosinophilia
associated with GERD is a separate entity from eosinophilic esophagitis.
Another hypothesis is that EoE contributes to or causes GERD. Eosinophils produce substances
that are cytotoxic and other factors that may alter esophageal motility. For example, eosino‐
phils produce vasoactive intestinal peptide and PAF which can lower esophageal pressure,
inducing GERD.[77, 78] Secretion of IL-6 can weaken esophageal muscle contraction and
peristalsis.[79] In asthma, cytotoxic substances can damage tight junctions.[80] In the esoph‐
agus this could lead to increased permeability to acid and induce pain receptors and the clinical
symptoms of GERD.[81, 82]
Finally, one hypothesis blames GERD for EoE. GERD can cause inflammation and increase the
permeability of the esophageal epithelium; thereby allowing large molecules to enter. This
influx of gastric contents could include potential allergens that induce EoE.[72, 74, 83-85] In
addition, refluxed gastric contents can activate many eosinophil chemoattractants including
IL-8, PAF, eotaxin-1-3 and MIP-1α.[74, 85] Other non-eosinophil immune cells and inflamma‐
tory mediators can also be attracted to the esophagus after exposure to gastric material.[86]
Proving any of these is a complex task involving multiple pathways in the systemic and
gastrointestinal immune systems.
7. Proton pump inhibitors
Due to the complexity of the relationship between GERD and EoE, proton pump inhibitors
have been at the center of much therapeutic research. When esophageal eosinophils were first
described they were attributed to GERD. Therefore patients were treated with anti-acid
medications. As mentioned earlier, only some of these patients responded to this therapy.
These patients are now considered to have “proton pump inhibitor responsive eosinophilic
esophagitis” (PPI-REE) according to the 2011 consensus recommendations.[5] The consensus
statement does not recommend PPI as a sole treatment for patients with esophageal eosino‐
phils that are not responsive to PPI therapy. However, they state that even these patients could
be treated with a PPI in addition to other treatment for their EoE. The use of PPI in patients
with EoE is multifactorial. First, GERD may be a comorbid disease in these patients. These
patients may have additional symptomatic relief with PPI therapy. PPI are used in acid
suppression because of their inhibitory effect on the H+K+ATPase of the gastric parietal proton
pump cell.[87] According to some hypotheses the suppression of acid in the gastric reflux
contents could decrease the production of acid stimulated eosinophilic chemoattractants and
other inflammatory cytokines. Also, decreasing esophageal acid damage would decrease
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esophageal permeability and exposure to allergens which can induce eosinophilia. However,
PPI’s may affect esophageal eosinophilia through other mechanisms outside of acid suppres‐
sion. They have been found to have anti-inflammatory effects on epithelial and endothelial
cells. They have demonstrated inhibitory effects against eotaxin-3 production and decrease
the expression of adhesion molecules and other inflammatory cytokines.[88, 89] PPI’s also
display anti-oxidant properties, including scavenging hydroxyl radicals, preventing oxidative
damage, and increasing levels of other anti-oxidants.[90-94] Proton pumps are found on cell
types other than parietal cells including neutrophils and monocytes. In vitro studies have
demonstrated PPI’s inhibit the oxidative burst, impair phagocytosis, impair neutrophil
migration, and decrease expression of adhesion molecules on monocytes and neutrophils.
[95-98] Despite these added effects of PPI’s, they cannot be used alone to treat EoE.[5]
8. Food allergy and dietary therapy
The link between allergens and EoE has now been accepted; however, the best way to
determine which allergens are most responsible and in which patients is still an area under‐
going intense research. Food elimination was first described by Kelly, et al. in 1995 with
positive results.[99] Currently there are three frequently prescribed dietary therapies. First,
complete elimination diet using amino acid-based formula. Second, six food elimination diet
(SFED), which restricts milk, soy, eggs, wheat, tree nuts/peanuts, and fish/shellfish. Last,
targeted elimination diet (TED) based off of skin prick and atopy patch testing. This last
therapy sometimes includes combination of empiric six food elimination and targeted food
elimination.
In a study of EoE patients by Spergel, et al. they determined food allergen prevalence through
biopsy results and symptom reports. They found the most common food allergen, diagnosed
by both symptoms and biopsy findings, in these patients was milk. Most common food
allergens diagnosed with biopsy were milk, egg, wheat, followed by beef, soy and chicken.
The most common foods diagnosed by symptoms were milk, egg and soy.[3] This has been
substantiated in the EoE literature where many of the studies have also used skin prick testing
and atopy patch testing to determine contributing food allergens.[9, 10, 100-103] The most
common food allergies reported in the EoE literature are milk, eggs, soy, wheat, nuts (peanuts
and tree nuts), and fish/shellfish.[100, 104, 105]
Henderson et al., in a retrospective study compared complete food elimination, targeted
elimination diet based from skin prick and atopy testing and six food elimination diet to
determine the effectiveness of each therapy.[6] They identified ninety eight patients that were
proton pump resistant and non-steroid treated who went on dietary therapy. They rated
remission as complete (<1 eos/hpf), partial (1-15 eos/hpf) and non-remission (>15 eos/hpf).
Patients on complete elimination diet had significantly higher complete remission rate (<1 eos/
hpf) and lower non-remission rate than the targeted elimination diet. They concluded that the
complete elimination diet was superior to targeted elimination or the six food elimination diet
and there was no difference between SFED and TED.[6] Other studies have shown similar
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results with a histologic remission rate for compete elimination diet to be over 90%.[106]
Studies of SFED in adults and children have shown that majority of patients have complete
histologic response with rates varying from 64-85%. A greater proportion have significant
response even if it is not complete resolution.[102, 105, 107]
Gonsalves’ study of adults with EoE all patients had skin prick testing for aeroallergens and
food allergens.[107] In all patients food allergens tested included the food items in the SFED;
eggs, milk, peanuts, tree nuts, fish, shellfish, wheat, and soy, in addition to other foods self-
reported as exacerbating symptoms. They found the skin prick test was predictive of only 13%
of inciting agents. Also, 67% of the patients who had positive biopsy findings after reintro‐
duction of one of the foods in the SFED had tested negative for that food on SPT. In addition,
a recent meta-analysis found that allergy test result-directed food elimination remission rate
(<15 eos/hpf) was only 45.5%, with high variability of remission rate between studies.[108,
109] The finding that elemental diet is superior to targeted elimination diet indicates that other
pathways are involved.
Aeroallergens/ pollen have also been studied as contributors of eosinophilic esophagitis.
Determining if aeroallergens are directly responsible for EoE via ingestion/inhalation or their
potential to cross react with sensitized foods is under research. Interestingly, common immune
epitopes (pan-allergens) exist between fruits, vegetables and pollen, and shellfish and insects
such as cockroach and dust mite. Some of the broad based allergy response may be linked such
as ragweed and melon or profiling in birch with celery and apple. In a mouse model, eosi‐
nophlic esophagitis could be induced by intranasal aeroallergen exposure.[110] In addition, in
both children and adults there is higher incidence of EoE diagnosis in seasons with high
aeroallergen counts.[111-113] Some have proposed that esophageal accumulation of eosino‐
philia in the background of aeroallergens is eotaxin and IL-5 dependent and others propose it
is through the TH2/IL-13 response.[114-116] Rayapudi, et al. tested the aeroallergen trigger
hypothesis via intranasal cockroach and dust mite allergen exposure on IL-5 and eotaxin levels
in CCR-3 deficient mice and wild-type mice. The deficient mice had a dampened esophageal
response to the allergens and they concluded indoor insect allergens induce IL-5 and eotaxin
mediated EoE.[61] In addition, it has been reported that patients with allergies treated with
sublingual pollen immunotherapy may have the unintended side effect of inducing EoE. A
recent meta-analysis concluded that 2.7% of patients undergoing oral immune therapy for IgE
mediated allergies develop EoE.[117]
Children and adults placed on an elemental diet show resolution of EoE in nearly all patients.
Elemental diet may be effective as they could also eliminate pollen pan-allergens and food
cross reactivity Issues. Elemental diets may also have effects unrelated to hypersensitivity
reactions. This has been investigated by Erwin,et al.[7] Patients with EoE were tested for IgE
sensitization using skin prick testing and a screening panel of specific IgE tests. They also tested
patients for non-IgE mediated food sensitivities with atopy patch testing. In order to determine
overall sensitization they included aeroallergens, common food allergens, cross-reactive
carbohydrate determinants, and common commensal elements of the GI tract (Candida
albicans and Helicobacter pylori) in the serum, skin prick testing and atopy patch testing. They
found that 20-30% of patients with EoE had no detectable immune sensitivity.[7] This suggests
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an intrinsic defect not relatable to allergic immune responses may be responsible. In some
patients non-IgE mediated responses are found in asthma, hay fever, and atopic dermatitis at
approximately 30% of each patient population. Investigators in these three diseases hypothe‐
size that it is possible to induce pure IL-5 response to stimuli without activating allergic
antibody (IgE) responses via IL-4 and IL-13.
9. Steroids
Although corticosteroids are not currently approved for use in EoE, they are frequently used
off-label in the treatment of PPI non-responsive esophageal eosinophilia. Dietary management
has shown to be effective however, due to compliance difficulties, topical steroids have been
used and have been found to be effective in majority of cases of EoE. The two most commonly
used preparations are swallowed aerosolized fluticasone propionate and oral viscous bude‐
sonide. Systemic corticosteroids can be used if topical steroids are not effective or the patient
needs rapid improvement in symptoms, like a food impaction. [118]
Four open-label trials have been conducted using fluticasone propionate.[68, 118-120] Two
trials were pediatric patients and two were in adult patients. All four studies reported a
significant symptom response rate. Complete symptom response ranged from 90-100% in
patients. In addition, all patients on fluticasone had significant decreases in the number of
esophageal eosinophils. Complete histologic response rates varied from 21-74% between the
studies.[68, 120]
In pediatric and adult placebo controlled trials using fluticasone or oral viscous budesonide,
patients on topical steroids had significant histologic response compared to placebo.[121-125]
Symptom response was variable in the studies. One study found no significant difference in
symptom response between the treatment and placebo groups. However, majority of the
patients in the topical steroid group had decrease in dysphagia symptoms, as opposed to less
than half in the placebo group.[121]
Four controlled trials have compared a proton pump inhibitor to topical steroids in the adult
population. Peterson, et al. compared fluticasone 440 μg twice daily to omeprazole 40 mg once
daily for 8 weeks. The histologic response between the two groups was not statistically
significant.[67] They also found no difference in dysphagia scores. Moaward, et al studied the
same drugs and doses.[126] They also had no statistical difference in histologic response
between the two groups at eight weeks. They did have a statistically significant difference in
dysphagia scores. The proton pump inhibitor had greater symptom response. The patients
with abnormal pH probes were stratified to both groups and these patients had response to
omeprazole but not to fluticasone.
Francis, et al. in a prospective trial, compared patients with esophageal eosinophilia who had
positive pH probe results compared to patients with negative pH probe results.[127] The
positive pH probe patients were prescribed omeprazole 40 mg twice daily and the patients
with negative pH probe results were treated with oral viscous budesonide 1 mg twice daily.
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The symptom and histologic response rates between the omeprazole and steroid groups was
not statistically significant.
Dellon, et al. compared two topical steroid treatments; oral viscous budesonide 1 mg twice
daily to nebulized then swallowed budesonide 1 mg twice daily in a randomized trial.[128]
They performed scintigraphy to measure esophageal mucosal contact time with the drug. The
oral viscous budesonide had statistically significant more mucosal contact time than the
nebulized then swallowed budesonide. This correlated with a significant decrease in eosino‐
phil counts in the oral viscous budesonide group. Both groups showed improvement in
symptoms and symptom response was not correlated with histologic response.
One  randomized,  comparator  controlled  study  has  been  done  in  pediatrics.  This  study
compared prednisone 1 mg/kg/day (40 mg maximum) to fluticasone propionate 220 μg QID
or 440 μg QID (depending on weight)  for  4  weeks.[129]  The study also had an 8 week
weaning protocol. Decrease in esophageal eosinophil counts at 4 weeks were significant in
both groups but the prednisone group had a greater degree of histologic response. Those
in  the  prednisone group had 100% symptom resolution at  4  weeks  and 97% of  flutica‐
sone patients had symptom resolution. Symptom relapse occurred at 12 weeks in approxi‐
mately 50% of patients, regardless of the treatment received. In addition, systemic adverse
effects were reported in 40% of the prednisone group; while the only adverse effect in the
fluticasone  group  was  esophageal  Candida  occurrence  in  15%  of  the  patients.  The  inci‐
dence of esophageal candidiasis as a result of topical steroid treatment for EoE has been
reported in studies of adults and pediatrics at rates ranging from 5-26%. Most report that
the infection was found incidentally on endoscopy, was not not symptomatic and was the
only adverse effect.[68, 120, 121, 123, 125, 126, 128]
Topical steroids have been shown to be effective at inducing histologic and symptom response.
However, length of therapy and role of maintenance therapy is still debated. Eosinophilic
esophagitis over time, can create fibrosis and subsequent strictures of the esophagus. Whether
or not this should be avoided even in asymptomatic patients is the basis of the maintenance
therapy debate. Straumann, et al. conducted a placebo controlled maintenance trial comparing
those with continued medication therapy versus placebo after steroid induced remission.[122]
They reported symptomatic recurrence rate of 64% and histologic relapse of 100% at 1 year in
the placebo group. However, others have found that more than half of patients were symptom
free after 3-11 years even if they had persistent esophageal eosinophilia.[130, 131] It is not
known which patients will develop fibrosis or if long-term topical steroid treatment will
prevent it.
The path of eosinophilic esophagitis to fibrosis is being investigated to help distinguish which
patients should receive long-term therapy to avoid esophageal fibrosis. Eosinophilic fibrosis
occurs as a consequence of tissue remodeling. As discussed earlier in the chapter, asthma has
been used as a model to understand EoE. These principles are used to understand the medi‐
ators responsible for remodeling in EoE. For example, IL-5 and IL-13 have shown to increase
collagen in animal models.[43, 51, 132, 133] In addition, other mediators including periostin,
TGF-B1, TSLP, Smad 3, and Siglec-F that have been studied in EoE pathogenesis are involved
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in tissue remodeling through multiple mechanisms.[43, 51, 134, 135] The mast cell-eosinophil
interaction has also shown to be important in the disease process. Mast cells are also producers
of the mediators and cytokines responsible for pathogenesis of EoE, includingTGFB1. Eosino‐
phils produce factors such as IL-9 that work in mast cell survival and recruitment. Mast cells
and eosinophils are both found in esophageal biopsies of EoE models. Murine models with
mast cell deficient mice show decrease in smooth muscle hypertrophy and proliferation.
Therefore indicating that mast cells may play a role in fibrosis and also esophageal dysmotility
in EoE.[55, 134, 136]
10. Future therapies
Treatment research is focused on understanding the mechanism behind the effectiveness of
dietary  and  steroid  therapy.  In  addition,  therapy  directed  at  specific  mediators  in  the
pathogenesis of EoE are also of great interest. Currently clinical trials are being conduct‐
ed  to  find  effective  non-steroidal  therapy.  Anti-IL-5,  anti-IL-13,  and  a  CRTH2  receptor
antagonist therapies are being studied in placebo controlled trials in adult and pediatric
EoE patients and they have all shown that they can induce significant decreases in number
of esophageal eosinophils compared to placebo.[137-141] However, their ability to resolve
symptoms has not been repeatedly demonstrated. An IL-4 α-subunit antagonist is show‐
ing promise in asthma patients and may be a potential therapy for EoE.[142-144] As our
knowledge  of  the  immune pathways  associated  with  EoE increase  then  other  receptors
could also be targets for therapies.
Eosinophilic esophagitis is a chronic immune mediated disease of the gastrointestinal tract.
The diagnosis  of  the disease and its’  subsequent  treatment requires  the expertise  of  the
allergist/immunologist and the gastroenterologist. Allergists have a unique understanding
of the pathophysiology of atopic diseases.  The diagnosis of EoE is likely to occur at the
time of atopic evaluation at an allergy clinic. The allergist can be of great assistance to the
gastroenterologist  in  assessing  food  allergic  individuals.  In  addition,  allergists  are  in  a
position to identify and treat, with immunotherapy or biologics, pollen associated EoE. In
our center a multi-disciplinary approach with GI and A/I has produced better outcomes
for  symptom  response  and  overall  improvement  of  disease  compared  to  a  fragmented
approach  to  care  (abstract  accepted).  The  allergist  needs  to  be  able  identify  atopic  pa‐
tients  who  have  risk  for  eosinophilic  esophagitis.  Likewise,  the  gastroenterologist  who
encounters  a  patient  with food impaction and discovers  esophageal  eosinophilia  should
consult  an  allergist  for  potential  triggers  and  possible  joint  treatment  approaches.  A
cooperative  multi-disciplinary  clinic  allows  for  coordinated  food  introductions  with
endoscopic follow-up evaluation. In addition, allergists routinely educate patients regard‐
ing food avoidance,  sources  of  contamination and cross-reactivity.  This  type of  detailed
education  has  been  a  proven  asset  to  dietary  compliance.  Allergists  will  also  have  the
experience with biologics, such as anti-IL5 and anti-IL-4 monoclonal antibodies, which may
not be currently used in gastroenterology practices.
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